Back to resultsA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Primary Purpose
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Nivolumab
Relatlimab
Carboplatin
Cisplatin
Paclitaxel
Nab-Paclitaxel
Pemetrexed
Sponsored by
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Stage IV Non-small Cell Lunch Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Relatlimab, Nivolumab, Chemotherapy
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization
- Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria
- No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease
Exclusion Criteria:
- Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy
- Untreated CNS metastases
- Leptomeningeal metastases (carcinomatous meningitis)
- Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease)
- Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Other protocol-defined inclusion/exclusion criteria apply
Sites / Locations
- Local Institution - 0160
- Local Institution - 0081
- Local Institution - 0139
- Local Institution - 0153
- Local Institution - 0011
- Local Institution - 0089
- Local Institution - 0121
- Local Institution - 0159
- Local Institution - 0002
- Local Institution - 0082
- Local Institution - 0129
- Local Institution - 0152
- Local Institution - 0097
- Local Institution - 0124
- Local Institution - 0162
- Local Institution - 0128
- Local Institution - 0165
- Local Institution - 0117
- Local Institution - 0156
- Local Institution - 0155
- Local Institution - 0084
- Local Institution - 0147
- Local Institution - 0148
- Local Institution - 0083
- Local Institution - 0149
- Local Institution - 0091
- Local Institution - 0001
- Local Institution - 0092
- Local Institution - 0157
- Local Institution - 0037
- Local Institution - 0021
- Local Institution - 0014
- Local Institution - 0073
- Local Institution - 0039
- Local Institution - 0029
- Local Institution - 0060
- Local Institution - 0038
- Local Institution - 0055
- Local Institution - 0086
- Local Institution - 0132
- Local Institution - 0057
- Local Institution - 0130
- Local Institution - 0138
- Local Institution - 0141
- Local Institution - 0109
- Local Institution - 0119
- Local Institution - 0085
- Local Institution - 0090
- Local Institution - 0126
- Local Institution - 0125
- Local Institution - 0127
- Local Institution - 0131
- Local Institution - 0063
- Local Institution - 0161
- Local Institution - 0116
- Local Institution - 0112
- Local Institution - 0107
- Local Institution - 0111
- Local Institution - 0072
- Local Institution - 0163
- Local Institution - 0120
- Local Institution - 0041
- Local Institution - 0016
- Local Institution - 0079
- Local Institution - 0008
- Local Institution - 0007
- Local Institution - 0144
- Local Institution - 0110
- Local Institution - 0102
- Local Institution - 0035
- Local Institution - 0006
- Local Institution - 0103
- Local Institution - 0045
- Local Institution - 0065
- Local Institution - 0062
- Local Institution - 0058
- Local Institution - 0108
- Local Institution - 0071
- Local Institution - 0050
- Local Institution - 0030
- Local Institution - 0133
- Local Institution - 0023
- Local Institution - 0106
- Local Institution - 0028
- Local Institution - 0009
- Local Institution - 0032
- Local Institution - 0059
- Local Institution - 0164
- Local Institution - 0019
- Local Institution - 0070
- Local Institution - 0020
- Local Institution - 0115
- Local Institution - 0013
- Local Institution - 0158
- Local Institution - 0053
- Local Institution - 0145
- Local Institution - 0036
- Local Institution - 0031
- Local Institution - 0080
- Local Institution - 0088
- Local Institution - 0099
- Local Institution - 0017
- Local Institution - 0052
- Local Institution - 0069
- Local Institution
- Arkhangelsk Clinical Oncological Dispensary
- FSBI ",Research Institute of Influenza named after A.A. Smorodintsev ",of the MoH of the Rus
- LLC Eurocityclinic
- Local Institution - 0042
- Local Institution - 0075
- Local Institution - 0137
- Local Institution - 0061
- Local Institution - 0051
- Local Institution - 0154
- Local Institution - 0048
- Local Institution - 0024
- Local Institution - 0074
- Local Institution - 0123
- Local Institution - 0043
- Local Institution - 0015
- Local Institution - 0104
- Local Institution - 0135
- Local Institution - 0101
- Local Institution - 0095
- Local Institution - 0067
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))
Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))
Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)
Part 2: Arm D (Nivolumab + PDCT)
Arm Description
Outcomes
Primary Outcome Measures
Treatment-related adverse events (TRAEs) leading to discontinuation within 12 weeks after the first dose
Part 1
Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent clinical review (BICR)
Part 2
Secondary Outcome Measures
Incidence of TRAEs leading to discontinuation
Part 1
Incidence of Adverse Events (AEs)
Part 1
Incidence of Serious Adverse Events (SAEs)
Part 1
Incidence of select Adverse Events (AEs)
Part 1
PFS per RECIST v1.1 by BICR
Part 2
Overall response rate (ORR) per RECIST v1.1 by BICR
Part 2
Duration of Response (DoR) per RECIST v1.1 by BICR
Part 2
Incidence of Adverse Events (AEs)
Part 2
Incidence of Serious Adverse Events (SAEs)
Part 2
Incidence of Treatment Related Adverse Events (TRAEs)
Part 2
Incidence of Immune-mediated Adverse Events (IMAEs)
Part 2
Incidence of select Adverse Events (AEs)
Part 2
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04623775
Brief Title
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Official Title
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 17, 2021 (Actual)
Primary Completion Date
May 28, 2024 (Anticipated)
Study Completion Date
September 16, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Keywords
Stage IV Non-small Cell Lunch Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Relatlimab, Nivolumab, Chemotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
420 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))
Arm Type
Experimental
Arm Title
Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))
Arm Type
Experimental
Arm Title
Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)
Arm Type
Experimental
Arm Title
Part 2: Arm D (Nivolumab + PDCT)
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Nivolumab
Intervention Description
Specified dose on specified days
Intervention Type
Biological
Intervention Name(s)
Relatlimab
Intervention Description
Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Intervention Type
Drug
Intervention Name(s)
Nab-Paclitaxel
Intervention Description
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Intervention Type
Drug
Intervention Name(s)
Pemetrexed
Intervention Description
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Primary Outcome Measure Information:
Title
Treatment-related adverse events (TRAEs) leading to discontinuation within 12 weeks after the first dose
Description
Part 1
Time Frame
Up to 10 months, from first participant's first dose
Title
Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent clinical review (BICR)
Description
Part 2
Time Frame
10 months after randomization, up to 21 months
Secondary Outcome Measure Information:
Title
Incidence of TRAEs leading to discontinuation
Description
Part 1
Time Frame
Up to 10 months, 30 days from participant's last dose
Title
Incidence of Adverse Events (AEs)
Description
Part 1
Time Frame
Up to 10 months, 30 days from participant's last dose
Title
Incidence of Serious Adverse Events (SAEs)
Description
Part 1
Time Frame
Up to 10 months, 30 days from participant's last dose
Title
Incidence of select Adverse Events (AEs)
Description
Part 1
Time Frame
Up to 10 months, 30 days from participant's last dose
Title
PFS per RECIST v1.1 by BICR
Description
Part 2
Time Frame
Up to approximately 3 years
Title
Overall response rate (ORR) per RECIST v1.1 by BICR
Description
Part 2
Time Frame
Up to approximately 2 years
Title
Duration of Response (DoR) per RECIST v1.1 by BICR
Description
Part 2
Time Frame
At 6 months, 12 months, and 18 months
Title
Incidence of Adverse Events (AEs)
Description
Part 2
Time Frame
Up to 21 months
Title
Incidence of Serious Adverse Events (SAEs)
Description
Part 2
Time Frame
Up to 21 months
Title
Incidence of Treatment Related Adverse Events (TRAEs)
Description
Part 2
Time Frame
Up to 21 months
Title
Incidence of Immune-mediated Adverse Events (IMAEs)
Description
Part 2
Time Frame
Up to 21 months
Title
Incidence of select Adverse Events (AEs)
Description
Part 2
Time Frame
Up to 21 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization
Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria
No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease
Exclusion Criteria:
Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy
Untreated CNS metastases
Leptomeningeal metastases (carcinomatous meningitis)
Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease)
Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Other protocol-defined inclusion/exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0160
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
Local Institution - 0081
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Local Institution - 0139
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Local Institution - 0153
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
Local Institution - 0011
City
Port Saint Lucie
State/Province
Florida
ZIP/Postal Code
34952
Country
United States
Facility Name
Local Institution - 0089
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Facility Name
Local Institution - 0121
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67214
Country
United States
Facility Name
Local Institution - 0159
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
Local Institution - 0002
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40241
Country
United States
Facility Name
Local Institution - 0082
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Facility Name
Local Institution - 0129
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68130
Country
United States
Facility Name
Local Institution - 0152
City
Howell
State/Province
New Jersey
ZIP/Postal Code
07731
Country
United States
Facility Name
Local Institution - 0097
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Local Institution - 0124
City
Johnson City
State/Province
New York
ZIP/Postal Code
13790
Country
United States
Facility Name
Local Institution - 0162
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Facility Name
Local Institution - 0128
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Local Institution - 0165
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Local Institution - 0117
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Local Institution - 0156
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Local Institution - 0155
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
Facility Name
Local Institution - 0084
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17604
Country
United States
Facility Name
Local Institution - 0147
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
Local Institution - 0148
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
Local Institution - 0083
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29607
Country
United States
Facility Name
Local Institution - 0149
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9179
Country
United States
Facility Name
Local Institution - 0091
City
Harlingen
State/Province
Texas
ZIP/Postal Code
78550
Country
United States
Facility Name
Local Institution - 0001
City
Tyler
State/Province
Texas
ZIP/Postal Code
75701
Country
United States
Facility Name
Local Institution - 0092
City
Spokane
State/Province
Washington
ZIP/Postal Code
99208
Country
United States
Facility Name
Local Institution - 0157
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Local Institution - 0037
City
Rio Cuarto
State/Province
Cordoba
ZIP/Postal Code
5800
Country
Argentina
Facility Name
Local Institution - 0021
City
Buenos Aires
State/Province
Distrito Federal
ZIP/Postal Code
C1426
Country
Argentina
Facility Name
Local Institution - 0014
City
Caba
State/Province
Distrito Federal
ZIP/Postal Code
1430
Country
Argentina
Facility Name
Local Institution - 0073
City
Capital
State/Province
LA Rioja
ZIP/Postal Code
5300
Country
Argentina
Facility Name
Local Institution - 0039
City
Viedma
State/Province
RIO Negro
ZIP/Postal Code
8500
Country
Argentina
Facility Name
Local Institution - 0029
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Local Institution - 0060
City
Cordoba
ZIP/Postal Code
5006
Country
Argentina
Facility Name
Local Institution - 0038
City
Cordoba
ZIP/Postal Code
X5004FHP
Country
Argentina
Facility Name
Local Institution - 0055
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
Local Institution - 0086
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
Local Institution - 0132
City
Tamworth
State/Province
New South Wales
ZIP/Postal Code
2340
Country
Australia
Facility Name
Local Institution - 0057
City
South Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Facility Name
Local Institution - 0130
City
Ballarat
State/Province
Victoria
ZIP/Postal Code
3350
Country
Australia
Facility Name
Local Institution - 0138
City
Bendigo
State/Province
Victoria
ZIP/Postal Code
3550
Country
Australia
Facility Name
Local Institution - 0141
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Local Institution - 0109
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Facility Name
Local Institution - 0119
City
Murdoch
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Facility Name
Local Institution - 0085
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Local Institution - 0090
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Local Institution - 0126
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution - 0125
City
Roeselare
State/Province
West-Vlaanderen
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Local Institution - 0127
City
Ghent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Local Institution - 0131
City
Ghent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Local Institution - 0063
City
Natal
State/Province
Rio Grande Do Norte
ZIP/Postal Code
59062 000
Country
Brazil
Facility Name
Local Institution - 0161
City
Ijui
State/Province
Rio Grande Do Sul
ZIP/Postal Code
98700-000
Country
Brazil
Facility Name
Local Institution - 0116
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
90050-170
Country
Brazil
Facility Name
Local Institution - 0112
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
91350-200
Country
Brazil
Facility Name
Local Institution - 0107
City
Barretos
State/Province
Sao Paulo
ZIP/Postal Code
14784-400
Country
Brazil
Facility Name
Local Institution - 0111
City
Santo Andre
State/Province
SAO Paulo
ZIP/Postal Code
09060-650
Country
Brazil
Facility Name
Local Institution - 0072
City
Rio de Janeiro
ZIP/Postal Code
20231-050
Country
Brazil
Facility Name
Local Institution - 0163
City
Sao Paulo
ZIP/Postal Code
04014-002
Country
Brazil
Facility Name
Local Institution - 0120
City
Sao Paulo
ZIP/Postal Code
08270-120
Country
Brazil
Facility Name
Local Institution - 0041
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
7500713
Country
Chile
Facility Name
Local Institution - 0016
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
7500921
Country
Chile
Facility Name
Local Institution - 0079
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
8420383
Country
Chile
Facility Name
Local Institution - 0008
City
Rennes
State/Province
Ille-Et-Vilaine
ZIP/Postal Code
35000
Country
France
Facility Name
Local Institution - 0007
City
Dijon cedex
ZIP/Postal Code
21079
Country
France
Facility Name
Local Institution - 0144
City
Le Mans
ZIP/Postal Code
72037
Country
France
Facility Name
Local Institution - 0110
City
Paris
ZIP/Postal Code
70005
Country
France
Facility Name
Local Institution - 0102
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
Local Institution - 0035
City
Paris
ZIP/Postal Code
75018
Country
France
Facility Name
Local Institution - 0006
City
Saint-Mande
ZIP/Postal Code
94160
Country
France
Facility Name
Local Institution - 0103
City
Berlin
ZIP/Postal Code
12351
Country
Germany
Facility Name
Local Institution - 0045
City
Berlin
ZIP/Postal Code
13585
Country
Germany
Facility Name
Local Institution - 0065
City
Essen
ZIP/Postal Code
45136
Country
Germany
Facility Name
Local Institution - 0062
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Local Institution - 0058
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Facility Name
Local Institution - 0108
City
Lowenstein
ZIP/Postal Code
74245
Country
Germany
Facility Name
Local Institution - 0071
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Facility Name
Local Institution - 0050
City
Paderborn
ZIP/Postal Code
33098
Country
Germany
Facility Name
Local Institution - 0030
City
Ravensburg
ZIP/Postal Code
88212
Country
Germany
Facility Name
Local Institution - 0133
City
Dublin
ZIP/Postal Code
D04 YN63
Country
Ireland
Facility Name
Local Institution - 0023
City
Dublin
ZIP/Postal Code
D09V2N0
Country
Ireland
Facility Name
Local Institution - 0106
City
Rome
State/Province
RA
ZIP/Postal Code
00144
Country
Italy
Facility Name
Local Institution - 0028
City
Candiolo
ZIP/Postal Code
10060
Country
Italy
Facility Name
Local Institution - 0009
City
Catania
ZIP/Postal Code
95125
Country
Italy
Facility Name
Local Institution - 0032
City
Genova Sampierdarena
ZIP/Postal Code
16149
Country
Italy
Facility Name
Local Institution - 0059
City
Milano
ZIP/Postal Code
20141
Country
Italy
Facility Name
Local Institution - 0164
City
Pesaro
ZIP/Postal Code
61122
Country
Italy
Facility Name
Local Institution - 0019
City
Siena
ZIP/Postal Code
53100
Country
Italy
Facility Name
Local Institution - 0070
City
Ciudad de Mexico
State/Province
Distrito Federal
ZIP/Postal Code
14050
Country
Mexico
Facility Name
Local Institution - 0020
City
Toluca de Lerdo
State/Province
Estado DE Mexico
ZIP/Postal Code
50090
Country
Mexico
Facility Name
Local Institution - 0115
City
Monterrey
State/Province
Nuevo LEON
ZIP/Postal Code
64710
Country
Mexico
Facility Name
Local Institution - 0013
City
San Pedro Garza Garcia
State/Province
Nuevo LEON
ZIP/Postal Code
66220
Country
Mexico
Facility Name
Local Institution - 0158
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands
Facility Name
Local Institution - 0053
City
Harderwijk
ZIP/Postal Code
3844 DG
Country
Netherlands
Facility Name
Local Institution - 0145
City
Gdynia
ZIP/Postal Code
81-519
Country
Poland
Facility Name
Local Institution - 0036
City
Lublin
ZIP/Postal Code
20-090
Country
Poland
Facility Name
Local Institution - 0031
City
Lublin
ZIP/Postal Code
20-093
Country
Poland
Facility Name
Local Institution - 0080
City
Olsztyn
ZIP/Postal Code
10-357
Country
Poland
Facility Name
Local Institution - 0088
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Local Institution - 0099
City
Cluj Napoca
State/Province
Cluj
ZIP/Postal Code
400015
Country
Romania
Facility Name
Local Institution - 0017
City
Craiova
State/Province
Dolj
ZIP/Postal Code
200385
Country
Romania
Facility Name
Local Institution - 0052
City
Craiova
State/Province
Jud. DOLJ
ZIP/Postal Code
200347
Country
Romania
Facility Name
Local Institution - 0069
City
Timisoara
State/Province
Timis
ZIP/Postal Code
300166
Country
Romania
Facility Name
Local Institution
City
Craiova
ZIP/Postal Code
200094
Country
Romania
Facility Name
Arkhangelsk Clinical Oncological Dispensary
City
Arkhangelsk
ZIP/Postal Code
163045
Country
Russian Federation
Facility Name
FSBI ",Research Institute of Influenza named after A.A. Smorodintsev ",of the MoH of the Rus
City
Saint Petersburg
ZIP/Postal Code
197376
Country
Russian Federation
Facility Name
LLC Eurocityclinic
City
Saint-Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Local Institution - 0042
City
Malaga
State/Province
Andalucia
ZIP/Postal Code
29011
Country
Spain
Facility Name
Local Institution - 0075
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41013
Country
Spain
Facility Name
Local Institution - 0137
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Local Institution - 0061
City
Las Palmas de Gran Canaria
State/Province
Las Palmas
ZIP/Postal Code
35016
Country
Spain
Facility Name
Local Institution - 0051
City
A Coruna
ZIP/Postal Code
15006
Country
Spain
Facility Name
Local Institution - 0154
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Local Institution - 0048
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Local Institution - 0024
City
Barcelona
ZIP/Postal Code
8036
Country
Spain
Facility Name
Local Institution - 0074
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Local Institution - 0123
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Local Institution - 0043
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Local Institution - 0015
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
Local Institution - 0104
City
St. Gallen
ZIP/Postal Code
9007
Country
Switzerland
Facility Name
Local Institution - 0135
City
Middlesborough
State/Province
Cleveland
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Facility Name
Local Institution - 0101
City
London
State/Province
Greater London
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Facility Name
Local Institution - 0095
City
Manchester
State/Province
Lancashire
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Facility Name
Local Institution - 0067
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
12. IPD Sharing Statement
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting
Learn more about this trial
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
We'll reach out to this number within 24 hrs